Sanofi (MIL:1SAN) Accounts Payable & Accrued Expense : €9,563 Mil (As of Dec. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Sanofi Accounts Payable & Accrued Expense?

Sanofi's quarterly accounts payable & accrued expense declined from Dec. 2023 (€9,265 Mil) to Jun. 2024 (€7,565 Mil) but then increased from Jun. 2024 (€7,565 Mil) to Dec. 2024 (€9,563 Mil).

Sanofi's annual accounts payable & accrued expense increased from Dec. 2022 (€8,521 Mil) to Dec. 2023 (€9,265 Mil) and increased from Dec. 2023 (€9,265 Mil) to Dec. 2024 (€9,563 Mil).

Sanofi Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sanofi's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Accounts Payable & Accrued Expense Chart

Sanofi Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

7,476.00

8,521.00

9,265.00

9,563.00

Sanofi Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															8,521.00	7,742.00	9,265.00	7,565.00	9,563.00

Sanofi Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (MIL:1SAN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY N:Mexico 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, Avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

No Headlines